Top Medical News

Futibatinib Approval Ushers in Targeted Therapy Option for Patients With Unresectable, Intrahepatic FGFR2-Positive Cholangiocarcinoma

December 6th 2022

Osheka Hansel, APRN, discusses the recent approval of futibatinib (Lytgobi) for patients with unresectable, locally advanced or metastatic intrahepatic FGFR2-positive cholangiocarcinoma.

Opinion: The Good Nurse Brings Safe Narcotic Handling to the Forefront of Nursing Minds

December 6th 2022

Sometimes nurses inappropriately handle high-risk medications. It is important that other nurses, especially those who work in pain management, hold colleagues accountable to promote patient safety.

Adjuvant Pembrolizumab Offers Patients With Resected Melanoma Better QOL Outcomes Than Ipilimumab, High-Dose Interferon

December 5th 2022

Adjuvant pembrolizumab demonstrated significantly better quality of life outcomes for patients with resected melanoma vs standard care.

Zimberelimab Monotherapy Proves Safe, Effective in PD-L1–Positive Cervical Cancer

December 5th 2022

Zimberelimab demonstrated encouraging efficacy with a tolerable safety profile in patients with PD-L1–positive recurrent or metastatic cervical cancer who had progressed after first- or subsequent-line, platinum-containing chemotherapy.

Nivolumab/Ipilimumab Induces Stark Overall Response Rate in Checkpoint Inhibitor–Naïve Merkel Cell Carcinoma

December 4th 2022

All 24 patients with Merkel cell carcinoma who received nivolumab plus ipilimumab responded to treatment, and 41% achieved complete responses.


Most Recent